In 2025, we introduced a new collaborative Biosimilar Taskforce to address this potentially transformative area. The taskforce coordinates activity across the system , optimise biosimilar uptake and ...
More than 80,000 adults and teenagers across England suffering with a chronic skin condition could have their lives transformed after NICE today (Tuesday, 24 February) recommended the first licensed ...
NICE recommended rimegepant in 2023 for treating migraine and preventing episodic attacks (between 4 and 14 migraines per month), and atogepant in 2024 for preventing both episodic and chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results